Norway, June 24 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, and Tcelltech GmbH, a biotechnology company developing non-viral, episomal DNA vector technology for the engineering of T cells, today jointly announce a research collaboration to combine Circio s circVec circular RNA expression technology with Tcelltech s double-stranded, non-integrating nanoSMAR vector platform for the development of next generation engineered T-cell therapies.Engineered T-cell therapies such as CAR-T have transformed the treatment of certain cancers. However, ex vivo manufacturing remains complex and the shift towards in vivo approaches currently relies on viral vectors that have s...